Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens

Recent data indicate excessive weight gain in treatment-naive adults with HIV commenced on antiretroviral therapy (ART) regimens containing tenofovir alafenamide (TAF) or the integrase strand transfer inhibitors (INSTIs) dolutegravir (DTG) and bictegravir.

Research

Clinical features and outcomes of COVID-19 and dengue co-infection: a systematic review

Dengue is the most common arboviral disease in the tropical and sub-tropical regions of the world. Like other regions, dengue-endemic areas have faced the additional public health and socio-economic impact of the ongoing coronavirus disease 2019 (COVID-19) pandemic.

Research

Seroprevalence and associated risk factors of selected zoonotic viral hemorrhagic fevers in Tanzania

To determine the seroprevalence of selected zoonotic viral hemorrhagic fevers (VHFs) and their associated risk factors in Tanzania.

Research

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including mRNA, adenoviral-vectored, protein subunit and whole-cell inactivated virus vaccines, have now reported efficacy in phase III trials and have received emergency approval in many countries.

Research

Maternal antibiotic exposure during pregnancy and hospitalization with infection in offspring: a population-based cohort study

Antibiotic exposure before or during pregnancy was associated with increased risk of childhood hospitalized infections

Research

Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with Pneumococcal Conjugate Vaccine

PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses

Research

Evaluation of safety and immunogenicity of a group a streptococcus vaccine candidate (mj8vax) in a randomized clinical trial

Intramuscular administration of novel acetylated peptide-protein conjugate vaccine candidate MJ8VAX was demonstrated to be safe and immunogenic

Research

An economic case for a vaccine to prevent group A streptococcus skin infections

A vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability

Research

Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveys

Direct and indirect effects on pneumococcal carriage post-PCV10 are likely to result in reductions in pneumococcal disease, including in infants too young to be vaccinated